AZN Astrazeneca Plc

TIDMAZN

RNS Number : 7947P

AstraZeneca PLC

22 November 2016

22 November 2016, 07:00

ASTRAZENECA HEAD AND NECK CANCER TRIALS

RESUME NEW PATIENT ENROLMENT AS FDA LIFTS

PARTIAL CLINICAL HOLD

AstraZeneca today announced that the US FDA has lifted the partial clinical hold on the enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines.

The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume recruitment shortly, without amendments to either protocol. AstraZeneca will progressively resume enrolment for all HNSCC trials across the participating sites in the US and globally, subject to national health authority and ethics committee approval where required. The status of active recruitment will be reflected on clinicaltrials.gov in the coming days.

The partial clinical hold on new patient enrolment was communicated on 27 October, after preliminary findings from ongoing clinical trials related specifically to head and neck cancer. The FDA lifted the partial clinical hold following a review of the comprehensive analysis provided by AstraZeneca of bleeding events that were observed as part of the routine safety monitoring of the Phase III KESTREL and EAGLE trials.

Monitoring of safety signals is an integral part of the development process for new medicines. Bleeding is a known complication in treatments of head and neck cancers primarily due to the nature of the underlying disease, the proximity of tumours to major blood vessels and use of prior cancer therapies, which may involve surgery and radiation.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Enquiries 
 Esra Erkal-Paler       UK/Global                                 +44 203 749 5638 
 
  Neil Burrows           UK/Global                                 +44 203 749 5637 
 Vanessa Rhodes         UK/Global                                 +44 203 749 5736 
 Karen Birmingham       UK/Global                                 +44 203 749 5634 
 Rob Skelding           UK/Global                                 +44 203 749 5821 
 Jacob Lund             Sweden                                    +46 8 553 260 20 
 Michele Meixell        US                                        +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                              +44 203 749 5712 
 Craig Marks            Finance, Fixed Income, M&A                +44 7881 615 764 
 Henry Wheeler          Oncology                                  +44 203 749 5797 
 Mitchell Chan          Oncology                                  +1 240 477 3771 
 Lindsey Trickett       Cardiovascular & Metabolic Diseases       +1 240 543 7970 
 Nick Stone             Respiratory                               +44 203 749 5716 
 Christer Gruvris       Autoimmunity, neuroscience & infection    +44 203 749 5711 
 US toll free                                                     +1 866 381 7277 
 

Adrian Kemp

Company Secretary, AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKBDPABDKQDB

(END) Dow Jones Newswires

November 22, 2016 02:02 ET (07:02 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025